MRKMerck Sharp & Dohme LLCSigning up patients
A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015)
Malignant Neoplasm
2Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +1.9
5 insiders sold shares within a month
Since Aug 13, 2026 · was worth 5, fading over time
Worry score2
Score over time
- Stage
- Phase 2
- Patients
- 250 (planned)
- Started
- Aug 11, 2025
- Main results expected
- Nov 4, 2027
- Fully finished
- Nov 4, 2027
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Progression-Free Survival (PFS) - All Cohorts
Measured over: Up to approximately 2 years
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 1.9, since 2026-08-13, fades (half-life)
Raw record changes
- none yet
Trial ID NCT06979596 · record last updated 2026-10-06 · checked 2026-11-09 15:47 UTC